Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206643 | 0.97 | FURIN (0.42) | FURINSIRT1HTTSMN1; SMN2SPHK1 | |
| SCHEMBL24728301 | 0.97 | FURIN (0.42) | FURINSIRT1HTTSMN1; SMN2SPHK1 | |
| SCHEMBL14234316 | 0.97 | FURIN (0.42) | FURINSIRT1HTTSMN1; SMN2SPHK1 | |
| SCHEMBL27291528 | 0.89 | FURIN (0.49) | FURINSIRT1HTTSMN1; SMN2SPHK1 | |
| SCHEMBL17133812 | 0.88 | FURIN (0.45) | FURINSIRT1HTTSMN1; SMN2SIRT2 | |
| SCHEMBL21122921 | 0.88 | FURIN (0.41) | FURINSIRT1HTTSMN1; SMN2 | |
| SCHEMBL17133811 | 0.88 | FURIN (0.45) | FURINSIRT1HTTSMN1; SMN2SIRT2 | |
| SCHEMBL16847753 | 0.88 | FURIN (0.43) | FURINSIRT1HTTSMN1; SMN2SIRT2 | |
| SCHEMBL24414345 | 0.88 | FURIN (0.41) | FURINSIRT1HTTSMN1; SMN2SPHK1 | |
| SCHEMBL21566843 | 0.88 | SIRT1 (0.41) | SIRT1SPHK1SIRT2SIRT3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200138968-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTIBODY DRUG CONJUGATE | REMEGEN, LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138968-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTIBODY DRUG CONJUGATE | MMAB, BTD, MGAM | FURIN 2094/4885SIRT1 3471/4885HTT 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.